Leap reports Phase I data from monotherapy arm of esophageal cancer trial

Leap Therapeutics Inc. (NASDAQ:LPTX) reported data from 16 patients with advanced esophagogastric cancer in the Phase I P102 trial showing that DKN-01 as monotherapy led to two partial responses, plus five cases of stable disease. Data were presented at the Barclays Global Healthcare Conference in Miami.

Leap has previously reported data from the combination arms of the open-label, U.S. trial (see BioCentury, Aug. 1, 2016)...